Clinical Scorecard: Romosozumab Enhances Trabecular Bone Score Adjusted for Tissue Thickness in Osteoporotic Women with Diabetes

At a Glance

Key Highlights

• Romosozumab (210 mg monthly for 12 months) followed by alendronate (70 mg weekly for 24 months) significantly improved lumbar spine aBMD and TBSTT compared to alendronate alone over 36 months.
• TBSTT accounts for regional lumbar spine soft tissue thickness, mitigating abdominal fat influence on trabecular bone score measurements in patients with diabetes.
• Romosozumab's improvements in bone parameters were maintained after transition to alendronate and correlated weakly with aBMD changes, suggesting independent effects on bone microarchitecture.

Guideline-Based Recommendations

Diagnosis

• Use lumbar spine dual-energy x-ray absorptiometry (DXA) scans to measure areal bone mineral density (aBMD).
• Assess trabecular bone microarchitecture using tissue thickness–adjusted trabecular bone score (TBSTT) derived from lumbar spine DXA scans to account for soft tissue effects.

Management

• Initiate treatment with monthly subcutaneous romosozumab 210 mg for 12 months in postmenopausal women with osteoporosis and type 2 diabetes at high fracture risk.
• Follow romosozumab with weekly oral alendronate 70 mg for at least 24 months to maintain bone density gains.
• Ensure daily supplementation with calcium and vitamin D during osteoporosis treatment.

Monitoring & Follow-up

• Perform lumbar spine DXA scans at baseline and periodically (e.g., months 12, 24, and 36) to monitor aBMD and TBSTT changes.
• Monitor for clinical fractures and adverse events throughout treatment.

Risks

• Consider increased fracture risk in patients with type 2 diabetes despite preserved aBMD due to altered bone microarchitecture.
• Be aware that abdominal fat can negatively influence unadjusted trabecular bone score measurements.

Patient & Prescribing Data

Postmenopausal women with osteoporosis and type 2 diabetes enrolled in the ARCH trial subgroup

Romosozumab followed by alendronate leads to greater and sustained improvements in lumbar spine aBMD and TBSTT compared to alendronate alone, potentially enhancing bone strength and reducing fracture risk.

Clinical Best Practices

• Use tissue thickness–adjusted TBS (TBSTT) to better assess bone microarchitecture in patients with diabetes, minimizing soft tissue interference.
• Consider anabolic therapy with romosozumab as first-line treatment in high-risk osteoporotic patients with type 2 diabetes.
• Transition to antiresorptive therapy (alendronate) after anabolic treatment to maintain bone density gains.
• Supplement patients with calcium and vitamin D to support bone health during pharmacologic treatment.

References

• ARCH Trial ClinicalTrials.gov